Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Artificial Intelligence (AI) In Drug Discovery Market Growth From $2.93 Billion In 2026 To $7.42 Billion By 2030 At A CAGR Of 26.2%

The market for artificial intelligence in drug discovery has experienced remarkable expansion lately, projected to ascend from $2.33 billion in 2025 to $2.93 billion in 2026, reflecting a formidable compound annual growth rate of 25.9%. This accelerated growth during the preceding period is largely attributable to heightened pharmaceutical research and development expenditures, the escalating intricacy found within drug discovery processes, a greater abundance of both biological and chemical data, the early integration of machine learning techniques within the field of bioinformatics, and a notable increase in cooperative ventures between pharmaceutical companies and technology firms.

The market for artificial intelligence in drug discovery is poised for substantial expansion in the coming years, projecting a rise to $7.42 billion by 2030 with a compound annual growth rate of 26.2%. This upward trajectory is fueled by several key drivers, including the escalating implementation of generative AI methodologies, a burgeoning need for highly personalized treatments, the broader integration of AI into clinical trial planning, increased financial backing for cloud-based research platforms, and a growing endorsement of AI’s role in pharmaceutical development by regulatory bodies. Significant developments anticipated during this period encompass a heightened utilization of AI for pinpointing therapeutic targets, a greater embrace of deep learning techniques for evaluating potential drug molecules, the more widespread incorporation of virtual screening systems, the advancement of AI-powered tools for refining drug candidates, and a concentrated effort to accelerate the overall drug development process.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp

Artificial Intelligence (AI) In Drug Discovery Market Expansion Drivers: What Is Shaping Future Growth?

The increasing requirement for tailored medical treatments is anticipated to be a primary catalyst for the expansion of artificial intelligence (AI) within the drug discovery sector. Personalized medicine, characterized by its focus on disease prevention, diagnosis, and treatment tailored to an individual’s unique genetic makeup, proteomic data, or biological characteristics, is seeing greater acceptance due to the heightened demand for accurate, individualized therapeutic strategies. These approaches aim to boost treatment efficacy while minimizing negative side effects. AI plays a crucial role in facilitating this transition by expediting the pinpointing of molecular targets, refining potential drug compounds, and improving the quality of clinical judgments across the entire drug development process. An illustrative example is the U.S. Food and Drug Administration’s approval of 26 novel personalized therapies in 2023, comprising twenty new molecular entities and six gene- or cell-based treatments, as reported by the Personalized Medicine Coalition in February 2024. Consequently, the escalating need for personalized medicine is a significant factor contributing to the growth of AI in drug discovery.

Artificial Intelligence (AI) In Drug Discovery Market Segment Outlook: Which Categories Are Expanding The Fastest?

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

Artificial Intelligence (AI) In Drug Discovery Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Companies at the forefront of the drug discovery sector are channeling significant capital into AI-driven enterprises, aiming to pinpoint and formulate novel therapeutic agents and subsequently make these advanced models accessible to other pharmaceutical entities. Such calculated investments serve to fuel the crucial research and development phases inherent in discovering new medications, a journey often characterized by substantial expenditure and extended timelines. This infusion of capital empowers companies to propel their drug discovery initiatives forward, ultimately facilitating the introduction of innovative treatments into the market. As an illustration, in July of 2023, Nvidia, a prominent American software developer, allocated $50 million to Recursion Pharmaceuticals, a US-based biotechnology firm employing artificial intelligence in its drug discovery endeavors. This financial backing is slated to bolster Recursion’s capacity to expedite the refinement of its AI models underpinning biological and chemical research, leveraging the cloud infrastructure provided by Nvidia.

Artificial Intelligence (AI) In Drug Discovery Market Key Companies And Competitive Benchmarking

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Access The Complete Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Artificial Intelligence (AI) In Drug Discovery Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europewas the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model